Filing summary: DelMar Pharmaceuticals, Inc. — Form 10-K
Entity and period: The supplied filing is for DelMar Pharmaceuticals, Inc., not Tuhura Biosciences, Inc. It covers the fiscal year ended June 30, 2017; it is not a 2016 Q4 report. Dollar amounts are U.S. dollars.
Business context and reporting period
DelMar was a clinical-stage cancer drug developer, principally focused on VAL-083. The candidate was being studied for glioblastoma (GBM), including a pivotal Phase 3 trial in recurrent, refractory GBM, and Phase 2 studies in MGMT-unmethylated GBM. The FDA had also allowed the company to proceed with a Phase 1/2 study in platinum-resistant ovarian cancer, subject to trial-site arrangements and approvals. VAL-083 was approved in China for chronic myelogenous leukemia and lung cancer; it was not approved for these indications elsewhere. The company reported no product commercialization in the period.
Financial performance and liquidity
| Metric | FY ended June 30, 2017 | FY ended June 30, 2016 |
|---|---|---|
| Revenue | No product revenue reported; the filing says near-term revenue is not expected | No product revenue reported |
| Research and development expense | $5.00 million | $3.36 million |
| General and administrative expense | $3.32 million | $2.85 million |
| Net loss | $8.08 million | $8.86 million |
| Loss per share | $0.74 | $0.83 |
| Cash used in operating activities | $8.02 million | $5.15 million |
| Cash and cash equivalents | $6.59 million | $6.16 million |
| Working capital | $6.57 million | $5.69 million |
| Total assets | $7.91 million | $6.36 million |
| Total stockholders’ equity | $6.58 million | $4.86 million |
Margins are not meaningful because the company had no product revenue. R&D expense rose 49%, mainly due to clinical and preclinical work, manufacturing and Phase 3 preparation, patent activity, and personnel costs. G&A rose 16%, including professional fees and Nasdaq-related costs. Net loss narrowed year over year, partly reflecting a fair-value gain on stock-option and derivative liabilities; these noncash revaluations can make reported results volatile.
Operating cash use increased, while financing provided $8.47 million net during FY2017, including $7.93 million from a share-and-warrant offering and $545,026 from warrant exercises. Current liabilities were $1.30 million. The balance sheet reported derivative liabilities of $61,228; the filing does not identify conventional borrowings as a material source of financing. The company had an accumulated deficit of $41.12 million.
Material changes, outlook, and risks
- Funding and dilution: After year-end, the company raised approximately $9 million net through an offering of 8 million common shares and warrants for 8 million additional shares, at $1.25 per share and related warrant. The filing also describes an April 2017 offering with approximately $9 million gross proceeds. Management estimated existing resources would fund operations beyond the next 12 months, but said further funding would be needed over the medium to longer term. Financing availability and terms are uncertain.
- Clinical outlook: STAR-3 was designed to enroll up to 180 patients and compare VAL-083 with investigator-selected salvage chemotherapy, with overall survival as the primary endpoint. Management estimated about two years to completion from trial initiation. The company also expected interim data from its recurrent MGMT-unmethylated GBM study during calendar 2018. These are forward-looking expectations, not results.
- Trial and product risks: VAL-083’s benefit remains unproven in the company’s trials. The prior GBM Phase 1/2 study was small and uncontrolled; reported subgroup survival comparisons were not randomized evidence. The principal dose-limiting toxicity was myelosuppression, particularly low platelets. Enrollment, safety, efficacy, regulatory review, manufacturing, and competition could delay or prevent approval.
- Other material risks: The company depended on third parties for trials and manufacturing, including a single manufacturer for Phase 3 supply; its backup manufacturer had not produced drug product. Management identified a material weakness in financial-reporting controls due to inadequate segregation of duties and said an external accounting consultant was engaged to assist with remediation. The independent auditor issued an unqualified opinion on the financial statements, but did not attest to internal-control effectiveness.
- Contingencies and unusual items: The filing reports no legal proceedings and no off-balance-sheet arrangements. FY2016 included a $100,868 out-of-period stock-option adjustment, which management said was not material. Series B preferred shares carried a 9% cumulative stock dividend and a low-single-digit royalty arrangement on applicable product sales; potential conversion and outstanding warrants/options create dilution risk.
Important facts for investors to verify
- Confirm the intended issuer and reporting period: the supplied document is DelMar’s FY2017 10-K, not a Tuhura Biosciences 2016 Q4 filing.
- Check subsequent financing proceeds, warrant terms, share counts, and the resulting fully diluted capitalization.
- Track actual STAR-3 enrollment, trial timelines, protocol status, and any FDA feedback against management’s stated expectations.
- Review clinical results in context, especially the limitations of historical and uncontrolled comparisons, and monitor hematologic safety findings.
- Assess the company’s cash runway against operating cash use, trial commitments, and its stated need for additional financing.
- Verify remediation of the material weakness and review future disclosures on internal controls and financial reporting.